CardiolRx™ — Topline data
mid-2027
Topline results anticipated in mid-2027 following expanded enrollment and study completion.Source filing
CRDL biotech catalysts & pipeline
CARDIOL THERAPEUTICS INC · Data as of 2026-10-25
Upcoming catalysts
cannabidiol — Clinical data readout
H1 2028
Proceeds strengthen balance sheet ahead of pivotal Phase III MAVERIC trial data readout in recurrent pericarditis and extends cash runway into H1 2028.Source filing